Omda Valuation

Q: What is the Fair Price of OMDA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

OMDA (NOK31) is trading below our estimate of [[fair value]] (NOK95.62)

Is OMDA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OMDA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: OMDA (NOK31) is trading below our estimate of fair value (NOK95.62)

Significantly Below Fair Value: OMDA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OMDA?

Key metric: As OMDA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for OMDA. This is calculated by dividing OMDA's market cap by their current earnings.
What is OMDA's PE Ratio?
PE Ratio	7x
Earnings	NOK 90.51m
Market Cap	NOK 629.55m

OMDA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.4x
Enterprise Value/EBITDA	13.9x
PEG Ratio	-0.2x

Price to Earnings Ratio vs Peers

How does OMDA's PE Ratio compare to its peers?

The above table shows the PE ratio for OMDA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	29.6x
CONTX ContextVision	19.4x	-4.4%	NOK 424.0m
CODE CodeLab Capital	0.5x	n/a	NOK 21.7m
MEDI Medistim	26.7x	4.1%	NOK 2.7b
4320 CE HoldingsLtd	71.9x	n/a	JP¥8.8b
OMDA Omda	7x	-32.9%	NOK 629.5m

Price-To-Earnings vs Peers: OMDA is good value based on its Price-To-Earnings Ratio (7x) compared to the peer average (29.6x).

Price to Earnings Ratio vs Industry

How does OMDA's PE Ratio compare vs other companies in the European Healthcare Services Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: OMDA is good value based on its Price-To-Earnings Ratio (7x) compared to the European Healthcare Services industry average (18.6x).

Price to Earnings Ratio vs Fair Ratio

What is OMDA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OMDA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	7x
Fair PE Ratio	13.5x

Price-To-Earnings vs Fair Ratio: OMDA is good value based on its Price-To-Earnings Ratio (7x) compared to the estimated Fair Price-To-Earnings Ratio (13.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst OMDA forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	NOK 31.00	NOK 44.00 +41.9%	20.5%	NOK 53.00	NOK 35.00	n/a	2
Nov ’25	NOK 31.00	NOK 42.00 +35.5%	16.7%	NOK 49.00	NOK 35.00	n/a	2
Oct ’25	NOK 31.30	NOK 44.50 +42.2%	10.1%	NOK 49.00	NOK 40.00	n/a	2
Sep ’25	NOK 37.50	NOK 46.50 +24.0%	14.0%	NOK 53.00	NOK 40.00	n/a	2
Aug ’25	NOK 41.30	NOK 46.50 +12.6%	14.0%	NOK 53.00	NOK 40.00	n/a	2
Jul ’25	NOK 35.00	NOK 46.50 +32.9%	14.0%	NOK 53.00	NOK 40.00	n/a	2
Jun ’25	NOK 34.30	NOK 49.00 +42.9%	18.4%	NOK 58.00	NOK 40.00	n/a	2
May ’25	NOK 36.00	NOK 49.00 +36.1%	18.4%	NOK 58.00	NOK 40.00	n/a	2
Apr ’25	NOK 30.50	NOK 49.00 +60.7%	18.4%	NOK 58.00	NOK 40.00	n/a	2
Mar ’25	NOK 26.50	NOK 54.50 +105.7%	26.6%	NOK 69.00	NOK 40.00	n/a	2
Feb ’25	NOK 33.10	NOK 55.50 +67.7%	27.9%	NOK 71.00	NOK 40.00	n/a	2
Jan ’25	NOK 37.00	NOK 55.50 +50.0%	27.9%	NOK 71.00	NOK 40.00	n/a	2
Dec ’24	NOK 39.00	NOK 55.50 +42.3%	27.9%	NOK 71.00	NOK 40.00	n/a	2
Nov ’24	NOK 30.00	NOK 58.50 +95.0%	9.4%	NOK 64.00	NOK 53.00	NOK 31.00	2
Oct ’24	NOK 33.90	NOK 58.50 +72.6%	9.4%	NOK 64.00	NOK 53.00	NOK 31.30	2
Sep ’24	NOK 39.00	NOK 59.00 +51.3%	10.2%	NOK 65.00	NOK 53.00	NOK 37.50	2
Aug ’24	NOK 41.50	NOK 60.00 +44.6%	8.3%	NOK 65.00	NOK 55.00	NOK 41.30	2
Jul ’24	NOK 41.30	NOK 60.00 +45.3%	8.3%	NOK 65.00	NOK 55.00	NOK 35.00	2
Jun ’24	NOK 45.70	NOK 60.00 +31.3%	8.3%	NOK 65.00	NOK 55.00	NOK 34.30	2
May ’24	NOK 37.50	NOK 56.50 +50.7%	20.4%	NOK 68.00	NOK 45.00	NOK 36.00	2
Apr ’24	NOK 37.50	NOK 56.50 +50.7%	20.4%	NOK 68.00	NOK 45.00	NOK 30.50	2
Mar ’24	NOK 35.00	NOK 56.50 +61.4%	20.4%	NOK 68.00	NOK 45.00	NOK 26.50	2
Feb ’24	NOK 41.50	NOK 56.50 +36.1%	20.4%	NOK 68.00	NOK 45.00	NOK 33.10	2
Jan ’24	NOK 38.00	NOK 56.50 +48.7%	20.4%	NOK 68.00	NOK 45.00	NOK 37.00	2
Dec ’23	NOK 37.10	NOK 60.50 +63.1%	17.4%	NOK 71.00	NOK 50.00	NOK 39.00	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.